Estrella Immunopharma (ESLA) risk factors, FY2024 10-K

Risks Related to the Equity Subscription Line and Shares Sold by the Selling Stockholders

1. 01It is not possible to predict the actual number of shares of Common Stock, if any, we will sell under the Common Stock Purchase Agreement to White Lion or the actual gross proceeds resulting from those sales
2. 02The sale and issuance of shares of Common Stock to White Lion will cause dilution to our existing securityholders, and the resale of the shares of Common Stock by White Lion, or the perception that such resales may occur, could cause the price of our securities to fall
3. 03Investors who buy shares of Common Stock from White Lion at different times will likely pay different prices
4. 04Sales of a substantial number of our securities in the public market by the Selling Stockholders or by our other existing securityholders could cause the price of our Common Stock and Warrants to fall

Risks Related to Estrella’s Operating History and Financial Condition

1. 05We are a clinical stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability
2. 06We will need substantial additional funds to advance development of product candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future product candidates and technologies
3. 07Members of our management team have limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company

Risks Related to the Development and Clinical Testing of Our Product Candidates

1. 08Our current product candidates are in either preclinical or clinical development. One or all of our current product candidates may fail in clinical development or suffer delays that materially and adversely affect their commercial viability
2. 09We may not be successful in our efforts to use and expand our use of the ARTEMIS® platform to expand our pipeline of product candidates
3. 10While our IND for EB103 was cleared by the FDA on March 2, 2023 and we believe our pipeline will yield additional INDs, we may not be able to file additional INDs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed
4. 11Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future
5. 12We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline
6. 13Clinical trials are expensive, time-consuming, and difficult to design and implement
7. 14If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
8. 15If clinical trials for our product candidates are prolonged, delayed, or stopped, we may be unable to seek or obtain regulatory approval and commercialize our product candidates on a timely basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue
9. 16If we decide to seek orphan drug designation for one or more of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation for our current or future product candidates that we may develop
10. 17We may not be able to conduct, or contract with others to conduct, animal testing in the future, which could harm our research and development activities

Risks Related to Third Parties

1. 18We rely on third parties to conduct our preclinical studies and our clinical trial for EB103, and plan to rely on third parties to conduct any clinical trials for our other product candidates, and those third parties may not perform satisfactorily
2. 19As a result, we may not be able to conduct these collaborations in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations
3. 20We may not realize the anticipated benefits of our collaboration agreement with Imugene
4. 21Changes in methods of product candidate manufacturing or formulation may result in the need to perform new clinical trials, which would require additional costs and cause delay

Risks Related to Our Business and Operations

1. 22If the market opportunities for our current and potential future product candidates, are smaller than we believe they are, our future product revenues may be adversely affected, and our business may suffer
2. 23Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan
3. 24As our current and potential future product candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development, regulatory, and manufacturing capabilities or contract with other organizations to provide these capabilities for us
4. 25Public opinion and scrutiny of immunotherapy approaches may impact public perception of Estrella and product candidates, or may adversely affect our ability to conduct our business and our business plans
5. 26Our potential future international operations may expose us to business, political, operational, and financial risks associated with doing business outside of the United States
6. 27Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations and prospects
7. 28Our employees, principal investigators, consultants, and commercial collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
8. 29If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected
9. 30Our business, operations, financial position and clinical development plans and timelines, could be materially adversely affected by the continuing military action in Ukraine and the war between Israel and Hamas

Risks Related to the Separation and Our Relationship with Eureka

1. 31We incurred significant costs in connection with the Business Combination and will incur incremental costs as a standalone public company
2. 32Certain of our officers or directors may have actual or potential conflicts of interest because of their equity interests in or positions with Eureka
3. 33We rely on Eureka for our research and development efforts

Risks Related to Our Intellectual Property

1. 34Our licenses and other material contracts may be invalid, unenforceable, or limited as to intellectual property and/or may impede, limit, or eliminate our ability to secure or protect our intellectual property, including in-licensed patent rights and any future developments
2. 35The patent protection and patent prosecution for some of our product candidates and technologies may be dependent on third parties
3. 36We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations
4. 37Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates
5. 38Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or product candidates
6. 39We or our licensors may be subject to lawsuits or litigation to protect or enforce our in-licensed patents or other intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products
7. 40We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business
8. 41Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our Common Stock to decline
9. 42If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
10. 43We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of third parties, including our employees’ or consultants’ former employers or their clients
11. 44Our licensors or we may be subject to claims challenging the inventorship of our in-licensed patents and other intellectual property
12. 45Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our licensors’ patent protection could be reduced or eliminated for non-compliance with these requirements
13. 46If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
14. 47Intellectual property rights do not necessarily address all potential threats to our business
15. 48If any negative data were to arise with respect to the use of our licensed technology in territories where such technology is licensed to a third party, it could negatively affect our ability to develop our product candidates in territories where we license such technology

Risks Related to Government Regulation

1. 49Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results
2. 50Furthermore, we expect to rely on our CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance
3. 51We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our current or potential future product candidates
4. 52Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
5. 53The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
6. 54Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
7. 55Healthcare legislative reform measures may have a material adverse effect on our business and results of operations
8. 56Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business
9. 57If we or our existing or potential future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our product candidates and may harm our reputation
10. 58If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business
11. 59Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
12. 60We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business
13. 61We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
14. 62Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
15. 63We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties
16. 64Our management team is not subject to non-competition restrictions if they terminate their employment with us

Risks Related to our Securities

1. 65Our Common Stock price may be volatile
2. 66Estrella may incur significant costs from class action litigation due to the expected stock volatility
3. 67We are a “controlled company” within the meaning of Nasdaq listing rules and, as a result, can rely on exemptions from certain corporate governance requirements that provide protection to shareholders of other companies
4. 68Estrella is an “emerging growth company” and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our Common Stock less attractive to investors and may make it more difficult to compare performance with other public companies
5. 69Future sales and issuances of Common Stock or rights to purchase Common Stock could result in additional dilution of the percentage ownership of Estrella stockholders and could cause Common Stock price to fall
6. 70The exercise by Estrella of its right to issue Common Stock pursuant to the Common Stock Purchase Agreement could cause substantial dilution, which could materially affect the trading price of Common Stock
7. 71We may be unable to sell shares to White Lion pursuant to the Common Stock Purchase Agreement if our Common Stock is delisted
8. 72Our Warrants may never be in the money, and they may expire worthless
9. 73We may redeem unexpired warrants prior to their exercise at a time that is disadvantageous to investors, thereby making our Warrants worthless
10. 74Our Warrants are exercisable for our Common Stock, which, upon exercise, would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders
11. 75Estrella’s internal control over financial reporting may not prevent or detect all errors or acts of fraud
12. 76Estrella has identified material weaknesses in its internal control over financial reporting which, if not corrected, could affect the reliability of Estrella’s consolidated financial statements, and have other adverse consequences
13. 77The identified material weaknesses, if not corrected, could result in a material misstatement to Estrella’s consolidated financial statements that may not be prevented or detected
14. 78Reports published by analysts, including projections in those reports that differ from Estrella’s actual results, could adversely affect the price and trading volume of our Common Stock
15. 79The obligations associated with being a public company will involve significant expenses and will require significant resources and management attention, which may divert from Estrella’s business operations
16. 80These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock, thereby depressing the market price of our Common Stock